Multiple Myeloma

ESH MM 2018 | Genomics shed light on targeted treatment for myeloma

ESH MM 2018 | Updated POLLUX results for early relapsed myeloma patients

ESH MM 2018 | Are BCL2 and MCL1 inhibitors the key against myeloma?

ESH MM 2018 | MRD sequencing test approved for MM in the US

ESH MM 2018 | Targeting BCMA with bispecific antibodies in R/R myeloma

ESH MM 2018 | Immunotherapeutics against multiple myeloma: it’s all about BCMA

ESH MM 2018 | MRD negativity using deep sequencing is a major prognostic factor in myeloma

ESH MM 2018 | Monoclonal antibodies: current and future potential

ESH MM 2018 | A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor

ESH MM 2018 | Where will we be in MM management 5 years from now?

ESH MM 2018 | Vaccines to prevent progression or relapse in multiple myeloma

Ann van de Velde

ESH MM 2018 | Real world data for len/dex in second-line myeloma: what does this tell us?

Evangelos Terpos

ESH MM 2018 | Real world data: bortezomib-based therapy for R/R myeloma

Evangelos Terpos

ESH MM 2018 | Continuous vs. fixed duration therapy for multiple myeloma?

Jesús San Miguel

ESH MM 2018 | Frontline transplant-ineligible MM treatment

ESH MM 2018 | Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)

1
2
3
4
5
…
42
Next